Radioimmunotherapy Consolidation using (131)I-Tositumomab for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Despite initial responses to chemoimmunotherapy, relapse and minimal residual disease (MRD) remain major issues in treatment of CLL/SLL patients. We administered 131I-tositumomab to patients in CR or PR after induction chemotherapy. Toxicities and rate of PR to CR conversion and MRD elimination were...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leuk Lymphoma
Egile Nagusiak: Shadman, Mazyar, Gopal, Ajay K., Kammerer, Britt, Becker, Pamela S., Maloney, David G., Pender, Barbara, Shustov, Andrei R., Press, Oliver W., Pagel, John M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4798884/
https://ncbi.nlm.nih.gov/pubmed/26133724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1067701
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak